In Key Opinion Leader Management, Quantity Does Not Equal Quality in Evaluating a Scientist's Real ...(ips with others in the community so thei...)

Date:9/30/2009

ips with others in the community so their ideas may not be spread around as easily to peers and colleagues. If you're an isolated person, it's hard for ideas to flow. Conversely, there are people that companies might dismiss because there is not much evidence of their importance as measured by publication counts. But we find them highly connected in roles such as advisers and trusted colleagues, or subject matter experts to the community."

Lnx Pharma uses "social network analysis" to decipher the real relationships in the medical and pharmaceutical research communities. Applying their proprietary technology to the universe of people and publications, they found across multiple disease categories that 50% of potentially valuable key scientific leaders were actually not the most frequently published or cited scientists. That is to say, if pharmaceutical companies are only considering volume and popularity as a metric for evaluating key advisers, they are missing up to half of the people who may be truly of importance.

Analyzing over a dozen disease categories for clients who engage the company for custom research, Lnx Pharma consistently found many previously undervalued or unknown KOLs, but more importantly they uncovered critical information about how people work and organize around specific ideas and topics. Importance can't be reliably measured by a list using one or two ranking criteria. Lnx Pharma technology allows deciphering of the complex web of relationship in the ecosystem of human expert networks, identifying relative positions of individuals in the network, based on multiple highly relevant criteria. The results are critical not only for Key Opinion Leader management, but also for overall pharmaceutical marketing research.

"Many of our clients have
'/>"/>

Source: PRWeb Copyright©2009 Vocus, Inc. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. European CHMP Adopts Negative Opinion on Cymbalta for the Treatment of Fibromyalgia
2. Alfacell Receives Going Concern Audit Opinion
3. Pharma Opinions Site Reviews the Breakthrough Drugs of Pharmaceutical Companies
4. Kuvan Receives Positive Opinion From CHMP for European Approval
5. SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms
6. FDA Advisory Committee Provides Opinion of DORIBAX(TM) for the Treatment of Hospital-Acquired Pneumonia
7. Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
8. Occlutech Clarifies Statement Regarding Favourable Opinion Obtained From AIPPI With Regard to Patents Held by AGA Medical
9. Memory Pharmaceuticals Receives Audit Opinion Containing Going Concern Qualification
10. New 300mg Loading Dose Tablet for Plavix(R) Receives Positive Opinion From the European Committee for Medicinal Products (CHMP)
11. Three Expert Opinion Journals now Publishing Original Research